Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.

[1]  R. García-Carbonero,et al.  LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer , 2022, Annals of Oncology.

[2]  Youngchul Kim,et al.  A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. , 2022, European journal of cancer.

[3]  K. Yonemori,et al.  Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. , 2022, The New England journal of medicine.

[4]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[5]  C. Nie,et al.  Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study , 2021, Frontiers in Oncology.

[6]  Fenghua Wang,et al.  Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis , 2021, Cell reports. Medicine.

[7]  Joseph Mugaanyi,et al.  Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma , 2021, Scientific Reports.

[8]  Y. Bai,et al.  A phase ib trial of assessing the safety and preliminary efficacy of a combination therapy of geptanolimab (GB 226) plus fruquintinib in patients with metastatic colorectal cancer (mCRC). , 2021 .

[9]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[10]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[11]  I. Soubeyran,et al.  Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial , 2021, Clinical Cancer Research.

[12]  Jason J Bergsbaken,et al.  Unleashing the power of immunotherapy and targeted therapy combinations: Advancing cancer care or discovering unknown toxicities? , 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[13]  B. Peng,et al.  Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. , 2021, American journal of cancer research.

[14]  M. Germani,et al.  Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge , 2020, Cancers.

[15]  S. Nomura,et al.  Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Möller,et al.  TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. , 2020, The Lancet. Oncology.

[17]  Anping Li,et al.  Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment , 2019, Molecular Cancer.

[18]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[19]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[20]  R. Jain,et al.  Dual PD-1 and VEGFR-2 blockade promotes vascular normalization and enhances anti-tumor immune responses in HCC. , 2019, Hepatology.

[21]  M. Shirley.  Fruquintinib: First Global Approval , 2018, Drugs.

[22]  Ying Cheng,et al.  Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial , 2018, JAMA.

[23]  Jin Li,et al.  A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[24]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[25]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[26]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[27]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.